Skip to content

Radiofrequency Chip for Localization of Non-Palpable Breast Lesions

Use of a Radiofrequency Chip for Localization of Non-Palpable Breast Lesions: A Comparison to Wire Localization

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03684408
Enrollment
38
Registered
2018-09-25
Start date
2018-10-18
Completion date
2021-04-19
Last updated
2022-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Tumor

Brief summary

The purpose of the project is to compare Radiofrequency identification device (RFID) localization technique with the current clinical standard wire localization technique. The Investigator's hypotheses is that the RFID localization technique is non-inferior to wire localization for breast lesions (tumors). The study will be conducted in two parts. The purpose of Part A is for physician training with the RFID device. Nine subjects will undergo RFID and wire localization prior to breast lesion excision. This will allow the breast radiologists and surgeons to become comfortable with RFID device placement and retrieval. Additionally, the investigators will pilot the data collection surveys and chart review methodology to be used in Part B. The purpose of Part B is to conduct a randomized clinical trial to assess whether RFID localization is non-inferior to wire localization for breast lesions. For this part, sixty subjects will be randomized to RFID (N=30) or wire localization (N=30) at time of enrollment. Surveys will be used to gather data from participants, radiologists, surgeons, and technologists/mammography nurses. A variety of data will be collected including, but not limited to, information on tumor size, location, depth; subject demographics; adequacy of tumor margins, re-excision rates, accuracy of wire or chip placement, and surgical complications.

Detailed description

As part of standard of care, participants will receive: an ultrasound (US) or mammographic guided localization; excisional breast surgery; and a follow-up visit in breast surgery clinic. As part of the research protocol, participants will receive a RFID chip for the localization procedure and complete surveys. Part A of this project is for physician training to master the technique of RFID placement and retrieval. On the day of surgery prior to going to the operating room, all participants will have the RFID placed first to allow radiologists to become familiar with placement of the RFID localizer. Participants will then immediately undergo wire localization. Either ultrasound or mammogram guidance will be used for the localization at the discretion of the performing radiologist. Surgeons will use a reader to locate the RFID chip during surgery. The wire will be present in the event the area of concern cannot be adequately located with the reader. Participants, radiologists, surgeons, breast surgery and radiology staff will complete surveys. Part B of this project is a prospective trial to examine safety, efficacy, operating room utilization patterns, and satisfaction with RFID versus wire localization. Participants will be stratified based on technique of localization (either US guidance or mammographic guidance). Participants will then be randomized to receive either the wire or RFID localization. There will be four visits: one pre-op breast surgery visit in which enrollment will occur, one radiology procedure visit for localization, one surgical visit, and one post-operative visit. This is the same number of visits as standard of care. Participants, radiologists, surgeons, breast surgery and radiology staff will complete surveys.

Interventions

DEVICERFID and Wire Localization

Both RFID and the standard of care wire localization will be performed for physician training.

DEVICERFID Localization

The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.

The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.

Sponsors

Health Beacons
CollaboratorINDUSTRY
University of Missouri-Columbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Women requiring image guided pre-operative breast tumor localization

Exclusion criteria

* Tumors deeper than 6 cm from the skin surface * More than one tumor requiring localization * Tumors requiring bracketing * Tumors requiring Magnetic Resonance Imaging localization * Inability to complete survey * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants With Successful LocalizationFrom the date of localization through the date of surgery up to 4 weeks; data collected during Visit 3 at time of surgeryWhether the surgeon was able to identify and remove the tumor

Secondary

MeasureTime frameDescription
Surveys of Satisfaction: ParticipantData collected during date of localization at Visit 2, up to approximately one month from baseline visitSurvey Question: Compared to expected, how uncomfortable was the localization? Scored on a scale of 1 to 5 with the best being 5
Surveys of SatisfactionData collected at baseline during Visit 1Surveys of Radiology Nurse ease of scheduling the localization procedure. Scored on a scale of 1 to 5 with the best being 5
Number of Participants With Tumor Incompletely ExcisedSurgical resection specimen collected during Visit 3, at time of surgeryNumber of participants with positive margin on pathology

Countries

United States

Participant flow

Participants by arm

ArmCount
RFID and Wire Localization
Part A of this project is for physician training to master the technique of RFID placement and retrieval. On the day of surgery prior to going to the operating room, all participants will have the RFID placed first to allow radiologists to become familiar with placement of the RFID localizer. Participants will then immediately undergo wire localization. Either ultrasound or mammogram guidance will be used for the localization at the discretion of the performing radiologist. Surgeons will use a reader to locate the RFID chip during surgery. The wire will be present in the event the area of concern cannot be adequately located with the reader. RFID and Wire Localization: Both RFID and the standard of care wire localization will be performed for physician training.
9
RFID Localization
Participants will be stratified based on technique of localization (either US guidance or mammographic guidance). They will then be randomized to receive either the wire or RFID localization. There will be four visits: one pre-op breast surgery visit in which enrollment will occur, one radiology procedure visit for localization, one surgical visit, and one post-operative visit. This is the same number of visits as standard of care. RFID Localization: The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
15
Wire Localization
Participants will be stratified based on technique of localization (either US guidance or mammographic guidance). They will then be randomized to receive either the wire or RFID localization. There will be four visits: one pre-op breast surgery visit in which enrollment will occur, one radiology procedure visit for localization, one surgical visit, and one post-operative visit. This is the same number of visits as standard of care. Wire Localization: The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
12
Total36

Baseline characteristics

CharacteristicRFID and Wire LocalizationRFID LocalizationWire LocalizationTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
2 Participants3 Participants5 Participants10 Participants
Age, Categorical
Between 18 and 65 years
7 Participants12 Participants7 Participants26 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants1 Participants0 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
9 Participants14 Participants12 Participants35 Participants
Sex: Female, Male
Female
9 Participants15 Participants12 Participants36 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 90 / 150 / 12
other
Total, other adverse events
0 / 90 / 150 / 12
serious
Total, serious adverse events
0 / 90 / 150 / 12

Outcome results

Primary

Number of Participants With Successful Localization

Whether the surgeon was able to identify and remove the tumor

Time frame: From the date of localization through the date of surgery up to 4 weeks; data collected during Visit 3 at time of surgery

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
RFID and Wire LocalizationNumber of Participants With Successful Localization9 Participants
RFID LocalizationNumber of Participants With Successful Localization15 Participants
Wire LocalizationNumber of Participants With Successful Localization12 Participants
Secondary

Number of Participants With Tumor Incompletely Excised

Number of participants with positive margin on pathology

Time frame: Surgical resection specimen collected during Visit 3, at time of surgery

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
RFID and Wire LocalizationNumber of Participants With Tumor Incompletely Excised0 Participants
RFID LocalizationNumber of Participants With Tumor Incompletely Excised0 Participants
Wire LocalizationNumber of Participants With Tumor Incompletely Excised0 Participants
Secondary

Surveys of Satisfaction

Surveys of Radiology Nurse ease of scheduling the localization procedure. Scored on a scale of 1 to 5 with the best being 5

Time frame: Data collected at baseline during Visit 1

Population: Not relevant for Part A. Since our breast surgeons were not experienced with using the RFID device, Part A consisted of performing the procedure with the RFID device prior to starting data collection for this outcome. This was done so that the surgeons would have completed their learning curve on a new device before data collection for this outcome began.

ArmMeasureValue (MEAN)Dispersion
RFID LocalizationSurveys of Satisfaction4 score on a scaleStandard Deviation 0.51
Wire LocalizationSurveys of Satisfaction4 score on a scaleStandard Deviation 1.22
Secondary

Surveys of Satisfaction

Surveys of radiologist satisfaction with the localization procedure. Scored on a scale of 1 to 5 with the best being 5

Time frame: Data collected during date of localization at Visit 2, up to approximately one month from baseline visit

Population: Not applicable to part A. Since our breast surgeons were not experienced with using the RFID device, Part A consisted of performing the procedure with the RFID device prior to starting data collection for this outcome. This was done so that the surgeons would have completed their learning curve on a new device before data collection for this outcome began.

ArmMeasureValue (MEAN)Dispersion
RFID LocalizationSurveys of Satisfaction4 score on a scaleStandard Deviation 1.28
Wire LocalizationSurveys of Satisfaction5 score on a scaleStandard Deviation 1.21
Secondary

Surveys of Satisfaction: Participant

Survey Question: Compared to expected, how uncomfortable was the localization? Scored on a scale of 1 to 5 with the best being 5

Time frame: Data collected during date of localization at Visit 2, up to approximately one month from baseline visit

ArmMeasureValue (MEAN)Dispersion
RFID and Wire LocalizationSurveys of Satisfaction: Participant3.4 score on a scaleStandard Deviation 0.72
RFID LocalizationSurveys of Satisfaction: Participant3.7 score on a scaleStandard Deviation 0.85
Wire LocalizationSurveys of Satisfaction: Participant4.4 score on a scaleStandard Deviation 0.81

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026